Cargando…
Intratumoral Immunotherapy—Update 2019
Intratumoral immunotherapies aim to trigger local and systemic immunologic responses via direct injection of immunostimulatory agents with the goal of tumor cell lysis, followed by release of tumor‐derived antigens and subsequent activation of tumor‐specific effector T cells. In 2019, a multitude of...
Autores principales: | Hamid, Omid, Ismail, Rubina, Puzanov, Igor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066689/ https://www.ncbi.nlm.nih.gov/pubmed/32162802 http://dx.doi.org/10.1634/theoncologist.2019-0438 |
Ejemplares similares
-
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
por: Ludwig, Heinz, et al.
Publicado: (2010) -
Maintenance and Consolidation Therapy in Patients with Unresectable Stage III/IV Non-Small Cell Lung Cancer
por: Thatcher, Nicholas, et al.
Publicado: (2010) -
Endometrial Carcinoma: A Review of Chemotherapy, Drug Resistance, and the Search for New Agents
por: Moxley, Katherine M., et al.
Publicado: (2010) -
Optimizing Clinical Benefits of Bisphosphonates in Cancer Patients with Bone Metastases
por: Aapro, Matti, et al.
Publicado: (2010) -
Fatigue in Renal Cell Carcinoma: The Hidden Burden of Current Targeted Therapies
por: Larkin, James M.G., et al.
Publicado: (2010)